Dear editor
I read "Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials" published in May 2015 by Liu et al. 1 The purpose of this article was to report the meta-analysis for the efficacy and safety of intravitreal corticosteroid implants for macular edema. However, there are some factual errors which mean the current article is misleading and these errors need to be pointed out to the readers of Drug Design, Development and Therapy.
First point -from the title of the article, the reader is expecting to read about corticosteroids that are licensed for use for macular edema. At this point the author should have specified that the therapy area being reviewed is diabetic macular edema (DME) and that Retisert (fluocinolone acetonide) is not licensed for this indication. 2 
ILUVIEN
® (190 micrograms fluocinolone acetonide intravitreal implant in applicator) and Ozurdex (dexamethasone), 3 however, are indicated for the treatment of DME. Second point -ILUVIEN now has marketing authorizations in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, and the United Kingdom for the treatment of vision impairment associated with chronic DME, considered insufficiently responsive to available therapies. 4 Contrary to the statement in the "Discussion", in November 2014 ILUVIEN was approved by the US Food and Drug Administration for the treatment of DME in patients who have previously been treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. 5 Hence there are slight differences between the European and USA licenses (these are summarized in Table 1 ).
Third point -in Europe the license for ILUVIEN is based on efficacy data reported at 36 months in the FAME trials. 6 In Table 1 the authors cite Retisert, which is not the name of the licensed medicine, and support this with data from Campochiaro et al published in 2011. However, this is misleading as the study cited was performed with ILUVIEN and has now been superseded by Campochiaro et al in 2012 which reports the 3-year results. 6 Fourth point -the authors refer to the efficacy and safety data for ILUVIEN and Ozurdex but have not accurately presented the current data and corrected the data to reflect USA and European licensed data. Table 1 has been generated to help the reader understand the differences between pivotal trial data for ILUVIEN and Ozurdex 6,7 and the licensed indications for ILUVIEN in the USA and Europe. 6, 7 In conclusion, it is hoped that the inaccuracies that have been identified will help clarify that ILUVIEN ® is an approved therapy for the treatment of DME and available b. The primary endpoint for these studies at the end of 36 months was the average change in BCVA from baseline with one of the trials failing to reach its primary endpoint.
c. A total of 1,048 subjects were randomized. a. The FAMe trials were performed under a single protocol as randomized, doublemasked, sham injection-controlled, parallel-group, multicenter studies conducted over a 36-month period and included a pre-planned subgroup analysis to assess efficacy in chronic DME patients.
b. The primary endpoint in the FAMe trials was 24 months. The secondary endpoint was at 36 months (and the basis for the license and indication approved in Europe). Both FAME trials independently met their primary efficacy endpoints of $15 letter improvement in BCVA over baseline.
c. A total of 956 subjects were randomized. 
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Efficacy and safety of different doses of an SR corticosteroid implant in 17 European countries and also the USA. Moreover, there are differences between the use of ILUVIEN in Europe and the USA as well as between ILUVIEN and Ozurdex, both corticosteroids licensed for DME, and these differences are detailed in Table 1 to help avoid any unnecessary confusion.
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